Do analysts recommend BIVI or MGX?

Metagenomi has a consensus price target of $7.00, suggesting a potential upside of 480.91%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Is BIVI or MGX more profitable?

BioVie has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Metagenomi -384.61% -51.23% -36.62%

Does the media favor BIVI or MGX?

In the previous week, Metagenomi had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for BioVie. BioVie's average media sentiment score of 0.62 beat Metagenomi's score of 0.35 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TCRT or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TCRT or BIVI more profitable?

BioVie's return on equity of -101.15% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% BioVie N/A -101.15% -90.18%

Do analysts prefer BIVI or INMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, BIVI or INMB?

INmune Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A INmune Bio N/A N/A -$45.93M -$1.67 N/A

Is BIVI or INMB more profitable?

BioVie's return on equity of -101.15% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% INmune Bio N/A -103.03% -77.66%

Does the media prefer BIVI or INMB?

In the previous week, INmune Bio had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for BioVie. INmune Bio's average media sentiment score of 0.94 beat BioVie's score of 0.62 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BIVI or ATHE?

Alterity Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 186.34%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Alterity Therapeutics is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better valuation and earnings, BIVI or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is BIVI or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Alterity Therapeutics N/A N/A N/A

Does the media prefer BIVI or ATHE?

In the previous week, Alterity Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for BioVie. BioVie's average media sentiment score of 0.62 equaled Alterity Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BIVI or DWTX?

Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 700.00%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, BIVI or DWTX?

BioVie is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is BIVI or DWTX more profitable?

BioVie's return on equity of -101.15% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Dogwood Therapeutics N/A -108.57% -30.28%

Does the media prefer BIVI or DWTX?

In the previous week, Dogwood Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 2 mentions for BioVie. BioVie's average media sentiment score of 0.62 equaled Dogwood Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioVie (BIVI) Competitors

$1.37 -0.07 (-4.86%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+1.09%)

As of 07/24/2026 05:38 PM Eastern

Compare

BIVI vs. MGX, TCRT, INMB, ATHE, and DWTX

Should you buy BioVie stock or one of its competitors? MarketBeat compares BioVie with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioVie include Metagenomi (MGX), Alaunos Therapeutics (TCRT), INmune Bio (INMB), Alterity Therapeutics (ATHE), and Dogwood Therapeutics (DWTX). These companies are all part of the "pharmaceutical products" industry.

How does BioVie compare to Metagenomi?

BioVie (NASDAQ:BIVI) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

4.6% of BioVie shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Metagenomi has a consensus price target of $7.00, suggesting a potential upside of 480.91%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

BioVie has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Metagenomi	-384.61%	-51.23%	-36.62%

BioVie has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Metagenomi had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for BioVie. BioVie's average media sentiment score of 0.62 beat Metagenomi's score of 0.35 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioVie has higher earnings, but lower revenue than Metagenomi. BioVie is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Metagenomi	$22.33M	2.03	-$87.87M	-$2.30	N/A

Summary

Metagenomi beats BioVie on 12 of the 16 factors compared between the two stocks.

How does BioVie compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

BioVie's return on equity of -101.15% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
BioVie	N/A	-101.15%	-90.18%

Alaunos Therapeutics has a beta of -1.02, indicating that its stock price is 202% less volatile than the broader market. Comparatively, BioVie has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alaunos Therapeutics has higher revenue and earnings than BioVie. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	$3K	15,792.89	-$4.18M	-$2.13	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

In the previous week, BioVie had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat BioVie's score of 0.62 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Very Positive
BioVie	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Alaunos Therapeutics beats BioVie on 6 of the 11 factors compared between the two stocks.

How does BioVie compare to INmune Bio?

BioVie (NASDAQ:BIVI) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

INmune Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
INmune Bio	N/A	N/A	-$45.93M	-$1.67	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, INmune Bio had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for BioVie. INmune Bio's average media sentiment score of 0.94 beat BioVie's score of 0.62 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioVie has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

4.6% of BioVie shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioVie's return on equity of -101.15% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
INmune Bio	N/A	-103.03%	-77.66%

Summary

INmune Bio beats BioVie on 9 of the 12 factors compared between the two stocks.

How does BioVie compare to Alterity Therapeutics?

BioVie (NASDAQ:BIVI) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

In the previous week, Alterity Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Alterity Therapeutics and 2 mentions for BioVie. BioVie's average media sentiment score of 0.62 equaled Alterity Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioVie has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Alterity Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 186.34%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Alterity Therapeutics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

4.6% of BioVie shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 0.9% of BioVie shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alterity Therapeutics' return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats BioVie on 8 of the 10 factors compared between the two stocks.

How does BioVie compare to Dogwood Therapeutics?

BioVie (NASDAQ:BIVI) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 2 mentions for BioVie. BioVie's average media sentiment score of 0.62 equaled Dogwood Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioVie is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

4.6% of BioVie shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 0.9% of BioVie shares are owned by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 700.00%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioVie's return on equity of -101.15% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

BioVie has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

Summary

Dogwood Therapeutics beats BioVie on 8 of the 12 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIVI vs. The Competition

Export

Metric	BioVie	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.86M	$3.08B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-0.56	20.29	27.11	23.64
Price / Sales	N/A	481.80	512.89	89.27
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	0.14	4.13	10.28	6.07
Net Income	-$17.54M	$65.94M	$3.60B	$331.99M
7 Day Performance	-23.89%	-4.16%	-1.27%	-0.63%
1 Month Performance	-23.03%	-3.76%	-0.37%	-2.00%
1 Year Performance	-81.68%	9.94%	18.30%	13.62%

BioVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIVI BioVie	0.397 of 5 stars	$1.37 -4.9%	N/A	-81.9%	$10.86M	N/A	N/A	10
MGX Metagenomi	3.8992 of 5 stars	$1.32 flat	$7.00 +430.3%	-52.0%	$50.00M	$25.21M	N/A	236	Analyst Downgrade
TCRT Alaunos Therapeutics	1.0721 of 5 stars	$2.06 -1.0%	N/A	-34.9%	$49.72M	N/A	N/A	40	Positive News Gap Up
INMB INmune Bio	1.076 of 5 stars	$1.84 -1.1%	N/A	-41.7%	$48.72M	$50K	N/A	10	Analyst Downgrade
ATHE Alterity Therapeutics	3.2783 of 5 stars	$5.32 -1.1%	$13.00 +144.4%	-20.1%	$46.75M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIVI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioVie (BIVI) Competitors

BIVI vs. MGX, TCRT, INMB, ATHE, and DWTX

How does BioVie compare to Metagenomi?

Summary

How does BioVie compare to Alaunos Therapeutics?

Summary

How does BioVie compare to INmune Bio?

Summary

How does BioVie compare to Alterity Therapeutics?

Summary

How does BioVie compare to Dogwood Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioVie (BIVI) Competitors

BIVI vs. MGX, TCRT, INMB, ATHE, and DWTX

How does BioVie compare to Metagenomi?

Do insiders and institutionals have more ownership in BIVI or MGX?

Do analysts recommend BIVI or MGX?

Is BIVI or MGX more profitable?

Which has more volatility and risk, BIVI or MGX?

Does the media favor BIVI or MGX?

Which has better valuation & earnings, BIVI or MGX?

Summary

How does BioVie compare to Alaunos Therapeutics?

Is TCRT or BIVI more profitable?

Which has more risk and volatility, TCRT or BIVI?

Do insiders and institutionals hold more shares of TCRT or BIVI?

Which has preferable earnings and valuation, TCRT or BIVI?

Does the media refer more to TCRT or BIVI?

Do analysts prefer TCRT or BIVI?

Summary

How does BioVie compare to INmune Bio?

Which has stronger earnings & valuation, BIVI or INMB?

Do analysts prefer BIVI or INMB?

Does the media prefer BIVI or INMB?

Which has more volatility & risk, BIVI or INMB?

Do institutionals and insiders have more ownership in BIVI or INMB?

Is BIVI or INMB more profitable?

Summary

How does BioVie compare to Alterity Therapeutics?

Which has better valuation and earnings, BIVI or ATHE?

Does the media prefer BIVI or ATHE?

Which has more volatility and risk, BIVI or ATHE?

Do analysts prefer BIVI or ATHE?

Do institutionals & insiders hold more shares of BIVI or ATHE?

Is BIVI or ATHE more profitable?

Summary

How does BioVie compare to Dogwood Therapeutics?

Does the media prefer BIVI or DWTX?

Which has better earnings and valuation, BIVI or DWTX?

Do institutionals & insiders believe in BIVI or DWTX?

Do analysts rate BIVI or DWTX?

Is BIVI or DWTX more profitable?

Which has more risk and volatility, BIVI or DWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools